B · Normal
[Nomura: Target price of HK$138.29 and a "buy" rating for Kangfang Biologics] On September 30, Nomura issued a research report stating that it gave Kangfang Biologics a target price of HK$138.29 and a "buy" rating. Summit Therapeutics and its overseas partner Summit Therapeutics announced that Summit has received a US$2 billion strategic investment from AstraZeneca. AstraZeneca's $2 billion investment in Summit's convertible preferred shares represents approximately 12% of Summit's common stock (10.6% on a diluted basis).
Hong Kong stock trends 🕐 2026-09-30 15:02
#Hong Kong stock trends
Save as Image Generate a beautiful long image to share on Moments or in group chats Generate now ⬇
← Back to Telegraph

Related telegraphs

[Hong Kong stock midday review: Hang Seng Index fell 0.04% and Hang Seng Technol 09-30 12:04 [Most pharmaceutical stocks in Hong Kong stocks are strong, GenScript Biotech ro 09-30 09:46 [Hong Kong real estate stocks weakened and Vanke fell more than 11%] On Septembe 09-30 09:38 [Hong Kong’s new stock Huanchuang Technology rose more than 200% and was subscri 09-30 09:34 [Hong Kong real estate stocks fell nearly 6%] On September 30, as of press time, 09-30 09:28 [Hong Kong artificial intelligence stocks strengthened, Fourier rose nearly 7%] 09-30 09:23

Comments

0/500
Captcha (click to refresh)
No comments yet